While undermining pandemic preparedness efforts, the Health and Human Services Department’s announcement that it would “wind down” messenger RNA vaccine projects related to influenza and COVID-19 will
While undermining pandemic preparedness efforts, the Department of Health and Human Services’ announcement that it would “wind down” messenger RNA vaccine projects related to influenza and COVID-19 wi
BridgeBio Pharma stunned Wall Street in April as it reported Attruby (acoramidis) sales that were triple consensus estimates in the first full quarter of its launch. Clearly, investors were hoping for
Amgen reported double-digit sales growth for more than a dozen of its products in the second quarter and talked about plans for expanding its use of artificial intelligence. But CEO Robert Bradway sai